^
BIOMARKER:
FGFR1 amplification
i
Other names: FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
Entrez ID:
Related biomarkers:
›
FGFR1 amplification
|
Hormone Receptor Positive Breast Cancer
|
FGFR1 amplification
|
Hormone Receptor Positive Breast Cancer
|
letrozole Resistant: B - Late Trials
|
letrozole Resistant: B - Late Trials
|
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
|
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
|
Gastric Cancer
|
FGFR1 amplification
|
Gastric Cancer
|
ABSK091 Sensitive: C2 – Inclusion Criteria
|
ABSK091 Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
|
Bladder Cancer
|
FGFR1 amplification
|
Bladder Cancer
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
TKI258 Sensitive: C2 – Inclusion Criteria
|
TKI258 Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
ABSK091 Sensitive: C2 – Inclusion Criteria
|
ABSK091 Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
Aromatase inhibitor Resistant: C3 – Early Trials
|
Aromatase inhibitor Resistant: C3 – Early Trials
|
FGFR1 amplification
|
HER2 Negative Breast Cancer
|
FGFR1 amplification
|
HER2 Negative Breast Cancer
|
ABSK091 Sensitive: C3 – Early Trials
|
ABSK091 Sensitive: C3 – Early Trials
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
Debio 1347 Resistant: C3 – Early Trials
|
Debio 1347 Resistant: C3 – Early Trials
|
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
|
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
|
TKI258 Sensitive: C3 – Early Trials
|
TKI258 Sensitive: C3 – Early Trials
|
FGFR1 amplification
|
HER2 Positive Breast Cancer
|
FGFR1 amplification
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
FGFR1 amplification
|
HER2 Positive Breast Cancer
|
FGFR1 amplification
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
FGFR1 amplification
|
HER2 Negative Breast Cancer
|
FGFR1 amplification
|
HER2 Negative Breast Cancer
|
pazopanib Sensitive: C4 – Case Studies
|
pazopanib Sensitive: C4 – Case Studies
|
FGFR1 amplification
|
NSCLC
|
FGFR1 amplification
|
NSCLC
|
M6123 Sensitive: D – Preclinical
|
M6123 Sensitive: D – Preclinical
|
FGFR1 amplification
|
Estrogen Receptor Positive Breast Cancer
|
FGFR1 amplification
|
Estrogen Receptor Positive Breast Cancer
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
FGFR1 amplification
|
Lung Cancer
|
FGFR1 amplification
|
Lung Cancer
|
TAS 120 Sensitive: D – Preclinical
|
TAS 120 Sensitive: D – Preclinical
|
FGFR1 amplification
|
CRC
|
FGFR1 amplification
|
CRC
|
eFT226 Sensitive: D – Preclinical
|
eFT226 Sensitive: D – Preclinical
|
FGFR1 amplification
|
Small Cell Lung Cancer
|
FGFR1 amplification
|
Small Cell Lung Cancer
|
TAS 120 + TAS-117 Sensitive: D – Preclinical
|
TAS 120 + TAS-117 Sensitive: D – Preclinical
|
FGFR1 amplification
|
NSCLC
|
FGFR1 amplification
|
NSCLC
|
eFT226 Sensitive: D – Preclinical
|
eFT226 Sensitive: D – Preclinical
|
FGFR1 amplification
|
Lung Cancer
|
FGFR1 amplification
|
Lung Cancer
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
|
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
|
ABSK091 Sensitive: D – Preclinical
|
ABSK091 Sensitive: D – Preclinical
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
afimoxifene Resistant: D – Preclinical
|
afimoxifene Resistant: D – Preclinical
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
PD 0173074 Sensitive: D – Preclinical
|
PD 0173074 Sensitive: D – Preclinical
|
FGFR1 amplification
|
Gastric Cancer
|
FGFR1 amplification
|
Gastric Cancer
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
FGFR1 amplification
|
Breast Cancer
|
FGFR1 amplification
|
Breast Cancer
|
eFT226 Sensitive: D – Preclinical
|
eFT226 Sensitive: D – Preclinical
|
FGFR1 amplification
|
Lung Cancer
|
FGFR1 amplification
|
Lung Cancer
|
ABSK091 + BI 6727 + BI2536 Sensitive: D – Preclinical
|
ABSK091 + BI 6727 + BI2536 Sensitive: D – Preclinical
|
FGFR1 amplification
|
Lung Cancer
|
FGFR1 amplification
|
Lung Cancer
|
BI 6727 + BI2536 Sensitive: D – Preclinical
|
BI 6727 + BI2536 Sensitive: D – Preclinical
|
